IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$415.93

ELV Valuation Report 2026-07-16

Elevance Health Inc. demonstrates resilience through strategic cost management and revenue diversification via its Carelon services segment, despite macroeconomic headwinds. Recent earnings exceeded expectations due to favorable medical cost control and disciplined expense management, prompting upward revisions to full-year earnings guidance. Investor focus remains on medical cost trends, with share price appreciation reflecting confidence in the company’s mitigation efforts. Capital allocation prioritizes Carelon and emerging technologies, aiming for long-term growth and enhanced shareholder value. While valuation remains premium, it’s supported by consistent revenue, strong cash flow, and capital return programs. Stable working capital and a defensive profile position the company well in the current environment. Strategic shifts over the past four quarters emphasize operational transformation, with acquisitions and technological integration driving long-term value. Risks include regulatory scrutiny, supply chain vulnerabilities, and competitive pressures, but proactive management and a balanced capital strategy suggest continued solid returns. The company’s focus on value-based care and expanding service offerings is expected to drive margin expansion and sustainable earnings power.

$306.42

JNJ Valuation Report 2026-07-16

Johnson & Johnson (JNJ) is a diversified healthcare company with revenue driven by Innovative Medicine and MedTech segments, consistently generating substantial free cash flow. Recent performance shows continued revenue growth, partially offset by biosimilar competition impacting products like Stelara, though key franchises like Darzalex and Tremfya are mitigating this. Strategic initiatives include integrating AI/robotics into MedTech and a focus on acquisitions (Intra-Cellular Therapies, Shockwave) alongside operational restructuring. While facing headwinds from inflation and potential regulatory changes, JNJ maintains a strong financial position and is actively reshaping its portfolio, including the separation of its Orthopaedics business. Recent balance sheet adjustments reflect funding for acquisitions and consistent shareholder returns through dividends and buybacks. Despite a robust pipeline and defensible market position, investor sentiment demands more pronounced outperformance, and the company’s risk profile has evolved with increasing legal and supply chain challenges. JNJ’s strategic focus on high-growth areas and efficient operations positions it for continued, though potentially cyclical, growth, with a long-term revenue target of $100 billion. Valuation analysis suggests a cautiously optimistic outlook, with a projected price range increasing from approximately $243 in the near term to over $306 long-term, contingent on successful execution and navigating evolving market dynamics.

$21.23

ANGO Valuation Report 2026-07-15

AngioDynamics is a medical device company focused on peripheral vascular, vascular access, and oncology solutions, generating revenue through direct sales and distribution. While recent revenue growth is evident, profitability remains a challenge, with the firm reporting net losses despite improvements. Strategic priorities include balancing investment in the RELIEF study (NanoKnife for BPH) with achieving profitability and positive cash flow, anticipating NanoKnife as a key growth driver. The company maintains moderate working capital intensity and has demonstrated revenue growth, but faces headwinds from macroeconomic factors like inflation and interest rates. Recent shifts include streamlining operations, restructuring, and increased R&D investment, alongside strategic divestitures to focus on high-margin products. While consistently investing in R&D, the company exhibits volatile cash flow and a current ratio that has decreased relative to industry peers. Valuation suggests potential near-term downward adjustment, with long-term projections indicating significant appreciation contingent on successful execution of strategic initiatives and favorable market conditions. Overall, AngioDynamics presents a growth-oriented profile navigating a complex environment, requiring consistent profitability and successful clinical trial outcomes to realize value creation.

$19.98

SLP Valuation Report 2026-07-10

Simulations Plus, Inc. is a healthcare software and services provider specializing in drug discovery and development optimization. Revenue comes from software licenses, maintenance, and project services, but recent results show 7% overall growth masked by flat software revenue – a concerning trend given its historical importance to profitability. This has triggered securities law investigations from multiple firms due to concerns about financial disclosures. A proposed $18.50/share acquisition by Altaris, LLC has further complicated matters, prompting shareholder litigation questioning the fairness of the price. The company is investing in AI-driven drug development through a collaboration with NVIDIA, but faces headwinds from decelerating software sales, legal challenges, and macroeconomic factors. Stable GDP growth and a steady unemployment rate offer some support, but inflation and interest rates pose risks. Recent strategic shifts include acquisitions, a focus on operational efficiency, and a transition to higher-margin service revenue. While demonstrating improved gross margins, the company faces risks related to revenue recognition, regulatory scrutiny, and the successful integration of the Altaris acquisition. Valuation estimates suggest a potential near-term decline followed by modest long-term growth, currently trading at $18.265 with a projected one-year target of $18.38.

$32.64

NRIX Valuation Report 2026-07-10

Nurix Therapeutics operates in the high-risk, capital-intensive biotechnology sector, developing protein degradation therapies for oncology and inflammatory diseases. Its pipeline includes clinical assets like bexobrutideg (BTK degrader) – the focus of a significant $700M (up to $2.3B milestone-based) collaboration with Roche – alongside other programs in early stages. While currently unprofitable with increasing net losses, the Roche deal provides crucial non-dilutive funding and validates its lead asset, extending its cash runway. Preliminary clinical data for bexobrutideg in CLL shows promising efficacy with a 92.9% objective response rate and 22.1-month progression-free survival. Strategic partnerships with Gilead, Sanofi, and Pfizer further support pipeline advancement. Financially, Nurix relies on external funding, demonstrated by multiple equity offerings, but the Roche collaboration mitigates immediate dilution. Macroeconomic factors present both opportunities (stable GDP) and challenges (inflation, rising interest rates). The company’s recent management evolution emphasizes innovation and operational efficiency, while its risk profile has shifted towards intellectual property, regulatory hurdles, and financial dependency. Ultimately, success hinges on clinical validation, regulatory approval, and effective commercialization of its pipeline. Current valuation reflects optimism predicated on bexobrutideg’s potential.

$11.76

REPL Valuation Report 2026-06-30

Replimune Group operates in a high-risk, capital-intensive biotechnology sector developing oncolytic immunotherapies. Currently funded by grants and collaborations, the firm experiences operating losses and relies on equity/debt financing. Its core strategy centers on RP1, a modified herpes virus undergoing BLA resubmission for advanced melanoma – approval is critical for transitioning to a revenue-generating entity. Additional pipeline candidates, RP2 & RP3, are in early-stage evaluation. Recent BLA acceptance for RP1 spurred investor confidence, but commercial viability depends on manufacturing, reimbursement, and competition. Macroeconomic factors – stable GDP, persistent inflation, and interest rate stability – present both opportunities and challenges, impacting operational costs and capital access. The company’s financial health remains precarious, with a focus on managing cash burn and optimizing capital allocation. Strategic shifts over the past four quarters demonstrate adaptation to regulatory hurdles and market conditions, prioritizing clinical development and internal manufacturing. Despite a complex risk landscape – regulatory scrutiny, supply chain fragility, competitive disruption – Replimune aims to establish a diversified immunotherapy portfolio. Valuation models suggest a potential near-term decline followed by gradual recovery, contingent on successful execution of its pipeline and favorable market conditions.

$22.32

IVF Valuation Report 2026-06-23

INVO Fertility operates a vertically integrated network of fertility clinics and develops novel therapies, balancing stable revenue from services with higher-risk pharmaceutical development. Recent 23% revenue growth is offset by Nasdaq delinquency regarding delayed financial filings, posing a delisting risk and restricting capital access. A restructuring eliminated preferred stock liabilities, strengthening the balance sheet, crucial given the capital-intensive nature of the sector. Efficient working capital management and careful evaluation of clinic acquisitions are vital for sustainable growth. Valuation requires a blended approach considering both service revenue and pharmaceutical pipeline risk. Macroeconomic stability supports potential demand, but inflationary pressures could impact disposable income. The company has shifted strategy towards clinic acquisitions, streamlining operations and focusing on established revenue streams. Recent risk escalation, including financial distress and regulatory scrutiny, has increased the Weighted Average Cost of Capital. Strategic positioning within the growing ART market, efficient customer acquisition, and a focus on underserved areas support continued growth, contingent on addressing compliance issues and maintaining financial flexibility.

$0.55

PBSV Valuation Report 2026-06-23

Pharma-Bio Serv, Inc. operates as a regulatory and technology transfer consultant across pharmaceuticals, biotech, and related industries, experiencing revenue volatility tied to project-based fees. Recent revenue growth (12.5% quarterly, 20% six-month) is moderate, with net income gains lagging, suggesting margin pressure from rising costs. Financial performance shows $2.7M quarterly and $5.0M six-month revenue, with limited net income ($0.2M/$0.3M). Valuation relies on comparable company analysis, complicated by the OTCQB listing and limited institutional coverage. The firm’s performance is linked to macroeconomic stability, with inflation posing a key risk to costs and client budgets. Management has shifted towards cost control and operational flexibility, including a move to a virtual model and dividend payments. Risks include regulatory changes, concentrated customer base (51.7% from four clients), and reliance on Puerto Rican tax incentives. While demonstrating resilience, PBSV faces challenges in consistently converting revenue into profit and maintaining a sustainable competitive advantage, requiring strategic cost management and diversification. Recent data indicates a cyclical pattern with fluctuating profitability and a need for improved asset utilization and working capital management.

$5.60

ANIX Valuation Report 2026-06-23

Anixa Biosciences is a clinical-stage biotechnology company developing immunotherapies and vaccines for oncology and infectious diseases, currently funded by R&D grants and future licensing/collaboration agreements. Its core strategy centers on the CER-T platform, a modified CAR-T technology targeting ovarian cancer, alongside preventative vaccines for breast and ovarian cancers, and a COVID-19 antiviral program. Recent data shows promising early survival benefits from the Phase 1 ovarian cancer trial (lira-cel) and positive immune responses in 74% of participants in the breast cancer vaccine trial, bolstering intellectual property protection. Financially, Anixa relies on equity and debt financing due to a lack of commercial products, necessitating careful monitoring of burn rate. Progress in clinical trials is crucial for securing partnerships and future funding. The company has shifted towards a focused biotech model, prioritizing capital efficiency and strategic collaborations. Macroeconomic factors present challenges – potential tighter monetary policy and inflationary pressures – but stable GDP growth offers some support. Anixa’s valuation hinges on successful clinical outcomes, demonstrating efficacy and securing favorable financing terms. Recent strategic evolution emphasizes capital efficiency, collaborative research, and a lean operational model, with a focus on oncology therapies and vaccines.

$231.80

DHR Valuation Report 2026-06-17

Danaher Corporation is a diversified industrial technology company with revenue from Life Sciences, Diagnostics, and Environmental & Applied Solutions, driven by recurring revenue from consumables and services. Recent acquisition of Masimo for $9.9 billion expands its diagnostics portfolio with AI-enabled technologies, though successful integration is key. The Life Sciences segment shows robust performance with 30%+ equipment order growth, fueled by bioprocessing and gene therapy demand. Despite positive indicators, the stock experienced recent declines. Danaher maintains strong free cash flow, moderate working capital, and a strategy of accretive acquisitions. Macroeconomic factors present challenges – inflation and interest rates – but Danaher’s innovation, premium pricing, and diversified revenue streams provide resilience. Strategic shifts over the past year emphasize growth through acquisitions and operational efficiency via the Danaher Business System. Risks include regulatory scrutiny, supply chain fragility, and competitive pressures. However, the company’s focus on recurring revenue, coupled with a robust balance sheet and strategic capital allocation, positions it for sustained growth in healthcare technology, particularly within bioprocessing, diagnostics, and environmental monitoring. Valuation suggests near-term appreciation to ~$202, with long-term potential reaching ~$232, though short-term volatility is anticipated.